Hello everyone again, News out on MLSC this morning:
Tuesday December 10 7:00 AM EDT
Medical Discoveries Announces Preliminary Test Results
Confirming MDI-P As Potential Antifungal Agent
SALT LAKE CITY, Dec. 10 /PRNewswire/ -- Medical Discoveries Inc today announced
successful test results evaluating the potential of its proprietary multipurpose antimicrobial agent,
MDI-P (Medical Discoveries Inc.(Pharmaceutical), against Candida albicans, a pathogenic
yeast/fungus, that colonizes the body's skin and mucous membranes resulting in disease, most often
during periods of lower natural resistance.
The in vitro (outside the human body) tests were conducted at the Infectious Disease Section of
Albany Medical College (Albany, N.Y.) and determined that, with one billion Candida albicans
organisms -- a substantially higher test challenge of organisms than typically studied -- MDI-P
killed up to 99 percent of the fungal organisms in less than one minute at a dilution of one to
10,000. Studies are now being considered to assess the agent's in vivo (inside the human body)
effectiveness in treating Candida- related disease. Additional tests at the college have confirmed
previous findings of MDI-P's in vivo nontoxicity, following intravenous administration in mice.
Diseases associated with Candida albicans range from painful, more commonly acquired thrush
and vaginal candidiasis to the infection of intravenous or catheter lines, leading ultimately to renal
failure or Candida encephalitis. Current treatments for serious Candida albicans infections bear
numerous toxic side effects, such as anaphylaxis (life-threatening hypersensitivity), thrombopenia
(decrease in blood-clotting platelets), convulsions, chills and anemia.
Marlin Toombs, director and vice president of Medical Discoveries, indicated that the test results
proved encouraging for a number of reasons. "Not only is there tremendous demand for a fast,
effective and nontoxic solution to this painful and often difficult-to-treat microorganism, but also we
have accomplished infection control at levels far above the industry standard and at a formula
dilution beyond what many had anticipated," said Toombs. "With in vivo toxicity results continuing
to support the safety of MDI-P, we have taken another important step toward formally submitting
the product for federal approval and offering MDI-P to a market in need of new microbicidal
treatments."
Medical Discoveries, Inc. is a development stage biotechnology company focused on
commercialization of certain antibiotic and antiviral technologies and agents, including processes
and equipment for the rapid sterilization of dental, veterinary and medical instruments. SOURCE
Medical Discoveries, Inc.
|
